@article{article30eb22c2,
title   = {ABX464 (obefazimod) for patients with COVID-19 at risk for severe disease: miR-AGE, a randomized, double-blind placebo-controlled trial},
author = {Giavina-Bianchi Júnior, Pedro Francisco and Cua, E and Risso, K and Mondain, V and Vissian, A and Joie, C and Pouletty, P and Gineste, P and Ehrlich, H. J and Kalil Filho, Jorge Elias},
year = {2023},
doi = {10.1016/j.jacig.2023.100140},
journal   = {Journal of allergy and clinical immunology: global}
}